External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer

External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer

Abiraterone acetate is approved for the treatment of castration-resistant prostate cancer (CRPC); however, its effects vary. An accurate prediction model to identify patient groups that will benefit from abiraterone treatment is therefore urgently required. The Chi model exhibits a good profile for...

Full description

Bibliographic Details
Main Authors: Yun-Jie Yang, Guo-Wen Lin, Gao-Xiang Li, Bo Dai, Ding-Wei Ye, Jun-Long Wu, Hu-Yang Xie, Yao Zhu
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2018-01-01
Series:Asian Journal of Andrology
Subjects:
abiraterone acetate; castration-resistant prostate cancer; external validation; nomogram; survival
Online Access:http://www.ajandrology.com/article.asp?issn=1008-682X;year=2018;volume=20;issue=2;spage=184;epage=188;aulast=Yang

Internet

http://www.ajandrology.com/article.asp?issn=1008-682X;year=2018;volume=20;issue=2;spage=184;epage=188;aulast=Yang

Similar Items